Goodman Financial Corp Nektar Therapeutics Transaction History

Goodman Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 21, 2021	SELL	$16.52 - $20.4 $1.76 Million - $2.17 Million	-106,238 Closed	0 $0
Q1 2021 Apr 28, 2021	SELL	$16.56 - $25.46 $34,842 - $53,567	-2,104 Reduced 1.94%	106,238 $2.13 Million
Q4 2020 Feb 02, 2021	SELL	$15.77 - $19.03 $171,199 - $206,589	-10,856 Reduced 9.11%	108,342 $1.84 Million
Q3 2020 Nov 09, 2020	SELL	$16.59 - $24.79 $37,178 - $55,554	-2,241 Reduced 1.85%	119,198 $1.98 Million
Q2 2020 Aug 07, 2020	SELL	$16.86 - $23.44 $48,101 - $66,874	-2,853 Reduced 2.3%	121,439 $2.81 Million
Q1 2020 May 14, 2020	BUY	$14.47 - $27.96 $92,347 - $178,440	6,382 Added 5.41%	124,292 $2.22 Million
Q4 2019 Jan 27, 2020	BUY	$15.87 - $23.12 $148,701 - $216,634	9,370 Added 8.63%	117,910 $2.55 Million
Q3 2019 Nov 07, 2019	BUY	$16.91 - $36.27 $208,229 - $446,628	12,314 Added 12.8%	108,540 $1.98 Million
Q2 2019 Aug 09, 2019	BUY	$31.0 - $36.3 $2.98 Million - $3.49 Million	96,226 New	96,226 $3.42 Million

144

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $167M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Goodman Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Goodman Financial Corp with notifications on news.